


# Lipid Algorithm For Type 1 and Type 2 Diabetes Mellitus in Adults

## Determine Fasting Lipid Profile (FLP) yearly



**Footnotes:**

<sup>1</sup> If a fibrate is combined with a statin, then fenofibrate is preferred rather than gemfibrozil due to risk of myositis and rhabdomyolysis.

## HMG CO-A REDUCTASE INHIBITORS LDL-C EQUIVALENCY IN PATIENTS WITH HYPERCHOLESTEROLEMIA\*

| FLUVASTATIN | PRAVASTATIN | LOVASTATIN | PITAVASTATIN | SIMVASTATIN | ATORVASTATIN | ROSUVASTATIN | EZETIMIBE/<br>SIMVASTATIN | APPROXIMATE<br>% LDL ↓ |
|-------------|-------------|------------|--------------|-------------|--------------|--------------|---------------------------|------------------------|
| 20 mg       | 10 mg       | 10mg       | —            | —           | —            | —            | —                         | 15–20                  |
| 40 mg       | 20 mg       | 20mg       | —            | 5–10mg      | —            | —            | —                         | 21–29                  |
| 80-XL       | 40–80mg     | 40 mg      | 1-2 mg       | 20mg        | 10mg         | —            | —                         | 30–38                  |
| —           | —           | 80 mg      | 4 mg         | 40mg        | 20mg         | 5–10mg       | 10/10 mg                  | 39–47                  |
| —           | —           | —          | —            | 80mg        | 40mg         | 20mg         | 10/20 mg                  | 48–54                  |
| —           | —           | —          | —            | —           | 80mg         | 40mg         | 10/40 mg                  | 55-59                  |
| —           | —           | —          | —            | —           | —            | —            | 10/80 mg                  | >59                    |

\* **Footnote:** This information is not completely based on head to head comparison

## REFERENCES

Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet*. 2003 Jun 14;361(9374):2005-16.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002 Jul 6;360(9326):7-22.

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet*. 2004 Aug 21-27;364(9435):685-96.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004 Jul 13; 110(2):227-39.

Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) *Am J Cardiol*. 1998 Mar 1;81(5):582-7.

Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. *Am J Cardiol*. 2005 Jan 1;95(1):120-2.

Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. *Prev Med*. 2003 Oct;37(4):283-90.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet*. 2005 Nov 26;366(9500):1849-61.

Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N Engl J Med*. 1999 Aug 5; 341(6):410-8.

Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet*. 2008 Jan 12;371(9607):117-25.

Saku K, Zhang B, Noda K. Randomized Head-to-Head Comparison of Pitavastatin, Atorvastatin, and Rosuvastatin for Safety and Efficacy (Quantity and Quality of LDL). *Circ J*. 2011 Apr 15. [Epub ahead of print] PMID: 21498906

Motomura T, Okamoto M, Kitamura T, Yamamoto H, Otsuki M, Asanuma N, Takagi M, Kurebayashi S, Hashimoto K, Sumitani S, Saito H, Kouhara H, Nshii K, Nakao M, Koga M, Sato B, Morimoto Y, Kasayama S. Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. *J Atheroscler Thromb*. 2009 Oct;16(5):546-52. Epub 2009 Sep 3. PMID:19729863